KBY Biotech Indexv0.0.34
Search
← Pipeline|POL-2127

POL-2127

Approved
By Polyphor
Source: Trial-derived·Trials: 1
Modality
Cell Therapy
MOA
RAS(ON)i
Target
CD19
Pathway
T-cell
RCC
Development Pipeline
Preclinical
~Apr 2010
→ ~Jul 2011
Phase 1
~Oct 2011
→ ~Jan 2013
Phase 2
~Apr 2013
→ ~Jul 2014
Phase 3
~Oct 2014
→ ~Jan 2016
NDA/BLA
~Apr 2016
→ ~Jul 2017
Approved
Oct 2017
→ Jun 2029
ApprovedCurrent
NCT08206345
1,384 pts·RCC
2017-10→2029-06·Recruiting
1,384 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-06-233.2y awayPh3 Readout· RCC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Approved
Recruit…
Catalysts
Ph3 Readout
2029-06-23 · 3.2y away
RCC
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08206345ApprovedRCCRecruiting1384VA
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-8662PfizerNDA/BLACD19GLP-1ag
NVS-6974NovartisPreclinicalCD19HPK1i
VoxarasimodMerck & CoPhase 1/2CD19AuroraAi
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
TirarelsinTG TherapeuticsNDA/BLACD19IL-17i